Crescent Biopharma, Inc. (NASDAQ:CBIO) — Market Cap & Net Worth
Market Cap & Net Worth: Crescent Biopharma, Inc. (CBIO)
Crescent Biopharma, Inc. (NASDAQ:CBIO) has a market capitalization of $292.50 Million ($292.50 Million) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15092 globally and #3499 in its home market, demonstrating a 3.88% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Crescent Biopharma, Inc.'s stock price $17.95 by its total outstanding shares 19500000 (19.50 Million).
Crescent Biopharma, Inc. Market Cap History: 2025 to 2026
Crescent Biopharma, Inc.'s market capitalization history from 2025 to 2026. Data shows growth from $231.27 Million to $350.02 Million (0.00% CAGR).
Crescent Biopharma, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Crescent Biopharma, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CBIO by Market Capitalization
Companies near Crescent Biopharma, Inc. in the global market cap rankings as of June 17, 2026.
Key companies related to Crescent Biopharma, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Crescent Biopharma, Inc. Historical Marketcap From 2025 to 2026
Between 2025 and today, Crescent Biopharma, Inc.'s market cap moved from $231.27 Million to $ 350.02 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $350.02 Million | +51.35% |
| 2025 | $231.27 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Crescent Biopharma, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $292.50 Million USD |
| MoneyControl | $292.50 Million USD |
| MarketWatch | $292.50 Million USD |
| marketcap.company | $292.50 Million USD |
| Reuters | $292.50 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Crescent Biopharma, Inc.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, inc… Read more